Ablative Solutions, Inc., is a company pioneering new approaches for the treatment of hypertension. Today the company announced the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor. Existing investors including Michigan Accelerator Fund, Novus Biotechnology and other individual investors also participated the Series D funding round.

Funds from the round will be used to complete clinical trials in support of U.S. and European regulatory submissions for the company’s minimally invasive renal denervation technology designed to help reduce blood pressure for people with uncontrolled hypertension, while taking antihypertensive medication.

Ablative Solutions’ alcohol-mediated renal denervation procedure is performed using the investigational Peregrine System™ Kit, which is engineered to target nerves known to influence the body’s regulation of blood pressure. The Peregrine Kit delivers dehydrated alcohol in small doses directly to the space outside of the renal artery to block the overactive signaling of the sympathetic nerves. This targeted treatment is designed to be performed in a rapid, straightforward procedure with minimal pain or discomfort for the patient.

“BioStar Ventures focuses on transformational health care investments, and we believe Ablative Solutions fits that model perfectly. We are enthusiastic about the company’s innovative approach to treating high blood pressure, a serious condition that impacts more than one billion people worldwide,” said Michael Fulton, M.D., senior managing director of BioStar Ventures, an investor in the company since its Series A round in 2012. “Ablative Solutions’ patented technology enables a streamlined procedure that has the potential to become an important adjunctive therapy to improve difficult-to-control blood pressure.”

Drug therapy and lifestyle changes are the most common treatments for hypertension. Medication non-adherence remains a serious and underappreciated limitation of drug therapy.1,2 More than half of those treated do not achieve their target blood pressure,3,4 highlighting the need for improved therapeutic options.

“Hypertension creates a significant burden on the healthcare system, increasing the risk of serious cardiovascular events and stroke,” said Gilde Healthcare’s Geoff Pardo. “We see tremendous potential for Ablative Solutions’ approach and believe the team has a solid plan for building the clinical data through the TARGET BP clinical program.”

“We have been supported the past few years by an amazing team of clinicians who, along with our very hard-working team, are committed to making this treatment available to patients,” said Ablative Solutions’ CEO and CMO Tim Fischell, M.D. “We are excited to have the support of this thoughtful and high-powered group of investors, which will allow the company to complete the studies required to seek regulatory approvals in Europe and in the United States.”

More on the Peregrine System Infusion Catheter can be found here.


1 Berra et al, Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension
Hypertension. 2016;68:297-306. DOI: 10.1161/HYPERTENSIONAHA.116.07464.
2 Azizi et al, Adherence to antihypertensive treatment and the Blood Pressure–lowering effects of renal Denervation in the renal Denervation for hypertension (Denerhtn) trial, Circulation. 2016;134:847–857.
DOI: 10.1161/CIRCULATIONAHA.116.022922.
3 CDC, https://www.cdc.gov/bloodpressure.
4 Williams et al, 2018 ESC/ESH Guidelines for the management of arterial hypertension, European Heart Journal (2018), 1–98 doi:10.1093/eurheartj/ehy339.